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Evaluation (GRADE) approach using the example of male human papilloma virus 
(HPV) vaccination Europe. Methods: A pan-European multidisciplinary expert 
group was established to develop an extended GRADE framework that includes 
explicit assessment of cost-effectiveness, medical needs, and patient aspects, ethi-
cal and social issues. Using an expert panel process, we assessed the feasibility of 
using this framework by applying it to male HPV vaccination in Europe. Studies were 
assessed using the specific framework tools; results and feasibility were discussed; 
and consensus was achieved through a modified Delphi method. Results: We 
identified three advisory committees (ACIP/USA; NACI/Canada; STIKO/Germany) 
using GRADE for vaccines assessment. Institutions handled data beyond vaccine 
efficacy and safety differently and did not formally grade economic evidence. We 
adopted the grading methodology of ACIP for the key factor ‘Benefits and Harms’ 
and developed modules for grading evidence type and quality of economic evalua-
tions (‘Economic Evaluation’) and for systematically assessing epidemiology, disease 
burden and unmet medical needs, as well as ethical, social and patient aspects 
(‘Values and Preferences’). The feasibility test demonstrated that all framework 
components were feasible in the case of HPV vaccination. Overall evidence type 
for cost-effectiveness was low with uncertainty in results. Cost-effectiveness was 
best, when all HPV-related diseases and outcomes were included and when assum-
ing low coverage in females and lower vaccine prices. ConClusions: The GRADE 
approach is applicable in assessing vaccinations and was successfully applied to 
HPV vaccination in males. The assessment of benefits and harms can be extended 
by explicit assessment of the evidence on cost-effectiveness and other key fac-
tors including unmet medical needs, and ethical, social and patient aspects. This 
extended framework can better inform policy- and decison makers.
CardiovasCular disease outComes researCh studies
Cv1
Challenges in modelling the Cost effeCtiveness of interventions in 
CardiovasCular disease
Burgers L.T., Redekop W.K., Severens J.L.
Erasmus University Rotterdam, Rotterdam, The Netherlands
objeCtives: Modelling is essential in performing economic evaluations for various rea-
sons. For example, modelling is necessary if extrapolation of short-term or intermediate 
results to long-term outcomes is required and numerous strategies need to be evaluated 
without direct evidence. However, modelling inherently poses challenges that need to 
be dealt with since models always represent a simplification of reality. The aim of this 
study is to identify and analyse the challenges in modelling the cost-effectiveness of 
cardiovascular disease (CVD) interventions. Methods: A questionnaire was sent to 
40 corresponding authors (systematically selected) of recent model-based economic 
evaluations of CVD interventions published in high-impact cardiovascular, health eco-
nomics and general medical journals. Respondents were asked to provide their own 
challenges and also rank the importance of challenges identified using a pilot version 
of the questionnaire distributed to 7 experienced researchers. Furthermore, we analysed 
the discussion sections of the papers to identify unmentioned challenges. Solutions, 
if available, were based on input from the respondents and the recommendations of 
the ISPOR-SMDM task force. Results: The systematic literature search identified 1720 
potentially relevant articles. The limit of 40 authors was reached after screening 294 
titles and abstracts. Beside the challenge of lack of data, preliminary results show that 
it was difficult to obtain a sufficiently valid, precise and accurate cost-effectiveness 
estimate due, for example, to interrelating clinical outcomes or extrapolating from sur-
rogate outcomes. Both challenges often exist in CEAs evaluating CVD prevention strate-
gies. ConClusions: The preliminary results of this study showed examples of CVD 
modelling challenges encountered during studies published in high-impact journals. 
Modelling guidelines do not provide sufficient assistance in resolving all challenges 
but it is probably unrealistic to expect this. Some of the reported challenges are specific 
to the type of intervention and disease, but most challenges are present in all types of 
interventions and diseases.
Cv2
appliCation of Behavioural eConomiCs to the understanding 
of adherenCe: does an individual’s time preferenCe influenCe 
adherenCe to mediCations?
Fargher E.A., Morrison V., Plumpton C.O., Hughes D.A.
Bangor University, Bangor, UK
objeCtives: There is general support that individual time preference affects health-
related behaviours. People with a high, positive time preference value their imme-
diate health higher than future health, even if presented with extreme scenarios 
of intertemporal choice. We hypothesised that adherence to medication requires 
trade-offs between immediate and delayed health benefits. Patients with lower 
time preference rates may be more adherent to medication as they place a higher 
value on the future benefits of adherence. Methods: Hypertensive adult patients 
across Europe were invited to complete a web-based survey that had been translated 
and piloted. Patients’ time preference was assessed (4-items) to calculate individual 
discount rates (%) in both short term (3-years) and medium term (6-years). Medication 
adherence was measured using the Morisky questionnaire (primary analysis) and the 
Medication Adherence Report Scale (MARS, secondary analysis). Sample size calculation, 
based on 5% one-sided confidence, assuming 30% non-adherence with Morisky measure 
indicated n= 323 per country. Missing data were imputed using multiple imputation in 
STATA. The significance of the association with adherence was assessed using the Wald 
test statistic. Results: 969 patients completed the questionnaire across England, Wales 
and Hungary, 79% of possible responses were observed. Short and medium term time 
preference rates in England, Wales and Hungary were in the expected directions, but 
the relationship was not statistically significant. Based on Morisky adherence - Wales 
(short): adherent 8.7%, non-adherent 9.4% (p= 0.541); (medium): adherent 4.7%, non-
adherent 5.0% (p= 0.611). England (short): adherent 7.8%, non-adherent 9.5% (p= 0.163); 
(medium): adherent 3.7%, non-adherent 4.5% (p= 0.095). Hungary (short): adherent 
19.0%, non-adherent 18.2% (p= 0.504); (medium): adherent 8.9%, non-adherent 8.6% 
to derive OS estimates for nilotinib and dasatinib of 13.0 and 13.4 years respectively 
(second-line CP). Using the same approach for bosutinib gives an OS of 12.8 years 
(third-line CP). The base-case in TA251 used a cumulative approach, where OS is 
equal to the duration of treatments in the pathway. If this method is applied to the 
TKIs in second-line CML (TA241), OS is reduced to approximately 9.4 and 10.1 years 
for nilotinib and dasatinib respectively (second-line CP). Similarly, bosutinib OS 
(third-line CP) is also reduced using this method and a substantial increase in the 
ICER is seen. ConClusions: There are methodological inconsistencies in NICE’s 
assessments of TKIs for CML. Applying the OS methodology from TA251 to TA241 
may have led to nilotinib not being recommended for routine use in the NHS. The 
impact of new methodologies on previous appraisal results and recommendations 
should be considered when assessing the validity of a new approach.
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addressing heterogeneity in Baseline risk of Copd exaCerBations 
using meta-regression
Cope S.1, Buckley F.2, Baldwin M.3, Kraemer M.4, Jansen J.2
1Mapi, Toronto, ON, Canada, 2Mapi, Boston, MA, USA, 3Novartis Pharmaceuticals UK Limited, 
Horsham, West Sussex, UK, 4Novartis Pharma AG, Basel, Switzerland
objeCtives: To evaluate differences across randomized controlled trials (RCTs) con-
cerning interventions for moderate to severe chronic obstructive pulmonary disease 
(COPD) in terms of baseline exacerbation rates and the association with treatment 
effects by means of a network meta-analysis (NMA). This NMA is performed based on 
RCTs evaluating the long-acting bronchodilators indacaterol 75/150/300µg OD, salme-
terol 50µg BID, formoterol 12µg BID, tiotropium bromide 18µg/5µg OD, and glycopyr-
ronium bromide 50µg OD. Methods: The rate of moderate or severe exacerbations 
was extracted from RCTs identified with a systematic literature review. A Bayesian NMA 
was used to synthesize the treatment effects of the different trials. The association 
between treatment effects and baseline exacerbation rate with placebo was assessed 
with a meta-regression model assuming a constant treatment-by-baseline risk interac-
tion term. Results: Twenty-four RCTs were included that differed mainly in terms of 
smoking status, COPD severity, use of inhaled corticosteroids, exacerbation definition, 
and exacerbation history. Across the RCTs the rate of exacerbations per patient year for 
patients in the placebo arm ranged from 0.40 to 1.91. Baseline risk was negatively associ-
ated with the rate ratios reflecting treatment effects across the RCTs. The coefficient for 
baseline risk was -0.35 (95% credible intervals: -0.49, -0.18). ConClusions: Based on a 
NMA of RCTs regarding the efficacy of long-acting bronchodilators in terms of the rate 
of exacerbations per patient year, baseline risk of exacerbations acts as a significant 
treatment effect modifier and should be accounted for in the model.
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systematiC review of statistiCal methods, results, and 
impliCations for poliCy makers
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objeCtives: Licensing and reimbursement of anticancer drugs should rely on evi-
dence from patient-relevant endpoints such as overall survival (OS). Nevertheless, 
evidence from surrogate endpoints may also be useful, as it may expedite the regula-
tory approval and coverage decisions of new therapies. It is therefore essential that 
candidate surrogate endpoints be properly validated. However, there is no consensus 
on statistical methods for such validation and on how the evidence thus derived 
should be applied by policy makers. Methods: We review meta-analyses of thera-
peutic interventions against advanced solid tumours published until December 2012 
that quantified the statistical association between progression-free survival (PFS) 
or time-to-progression (TTP) and OS. We assessed the suitability of the two surro-
gates using three current surrogate validation frameworks: Bucher’s framework, the 
German Institute of Quality and Efficiency in Health Care’s (IQWiG) framework and 
the Biomarker-Surrogacy Evaluation Schema (BSES3). Results: Thirty-one meta-
analyses were included which employed a variety of statistical methods to assess 
surrogate validity. The strength of the association between PFS or TTP and OS was 
generally low. The level of evidence (observation-level vs. treatment-level) available 
supporting an association between PFS or TTP and OS varied considerably by cancer 
type, by evaluation tools and was not always consistent even within one specific 
cancer type. ConClusions: Not in all solid tumours the treatment-level associa-
tion between PFS or TTP and OS has been investigated. According to the IQWiG’s 
framework, only PFS achieved acceptable evidence of surrogacy in metastatic colo-
rectal and ovarian cancer treated with cytotoxic agents, whereas in no indication 
did the two candidate endpoints achieve good evidence of surrogacy according to 
BSES3. Our study emphasises the challenges of surrogate-endpoint validation and 
the importance of building consensus on appropriate statistical techniques to exam-
ine surrogacy and on the development of evaluation frameworks for policy makers.
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framework for evidenCe assessment Based on grade and 
appliCation to hpv vaCCination in males in the european health 
Care Context
Siebert U.1, Sroczynski G.2, Baker P.3, Borget I.4, Castellsagué X.5, Chapman R.6,  
von Knebel-Doeberitz M.7, Mortensen G.L.8, La Torre G.9
1UMIT – University for Health Sciences, Medical Informatics and Technology / ONCOTYROL / Harvard 
University, Hall i. T./ Innsbruck / Boston, Austria, 2UMIT – University for Health Sciences, Medical 
Informatics and Technology, Hall i.T., Austria, 3Men’s Health Consultant, Brighton, UK, 4Institut 
Gustave Roussy, Villejuif, France, 5L’Hospitalet de Llobregat, Barcelona, Spain, 6Evidera, London, UK, 
7University of Heidelberg, German Cancer Research Center, Heidelberg, Germany, 8AnthroConsult, 
Aarhus C, Denmark, 9Sapienza University of Rome, Rome, Italy
objeCtives: To develop and apply an extended framework for evidence assess-
ment based on the Grading of Recommendations Assessment, Development and 
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large polyps, natural history of adenoma transition to cancer and importantly, 
adherence. CTC was found to be cost-effective in three studies, assuming the most 
favourable scenario. ConClusions: CTC has the potential to be a cost-effective 
CRC screening strategy when compared to COL. There is a strong need for a differ-
ential consideration of patient adherence and compliance to CTC and COL. Recent 
research shows that laxative-free CTC screening has the potential to become a viable 
alternative screening method for CRC as it can improve patient uptake of screening. 
This project is supported by the German Federal Ministry of Education and Research 
(BMBF) as part of the National Cluster of Excellence‚ Medical Technologies – Medical 
Valley EMN’ (Project grant No. 13EX1013B).
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market aCCess of implantaBle mediCal deviCes: evidentiary 
requirements aCross gloBal markets
Chawla A.S.1, Spinner D.S.1, Ransom J.F.2, Doyle J.2, Faulkner E.C.1
1Quintiles Consulting, Durham, NC, USA, 2Quintiles Global Consulting, Hawthorne, NY, USA
objeCtives: With tightening health system budgets, medical devices (MDs) are 
being increasingly scrutinized for their impact on overall health care cost. The evi-
dence bar for implantable MDs is particular high since most implantable devices 
are not reimbursed separately by payers, but via direct bundled payments to the 
provider. To characterize that trend, the objectives of this study were to: 1) Identify 
specific evidence criteria that maximally impact the payer decision, 2) Note differ-
ences in HTAs across global markets, and finally 3) Outline differences in evidence 
requirements between drugs and devices. Methods: A multimarket review of 
implantable MD HTAs and reimbursement decisions published from 2008-2013 was 
conducted. Identified by HTA Watch, HTAs included those from Australia, Belgium, 
Canada, France, Germany, Italy, the UK and the US. They spanned a variety of indi-
cations, including cardiovascular, orthopedic, neurological, trauma, among others. 
HTAs and reimbursement decisions were characterized for clinical and economic 
evidence requirements and apparent correlations and/or impacts on ultimate 
agency recommendation. Results: Evidence criteria evaluated by HTA agencies 
and payers primarily included: 1) Availability of supportive randomized controlled 
trials (RCTs), 2) Safety, 3) Efficacy/long-term outcomes, 4) Cost/cost-offsets/budget 
impact, and 5) Quality of-life improvement. In contrast to drug HTAs, clinician 
training and learning curve effects were often evaluated. Importantly, agencies 
recognized the challenge in demonstrating statistically- and clinically-significant 
evidence of improvement in outcomes. As such, many MDs were recommended 
on a restricted basis to specific patient subpopulations or on a coverage based 
on continued evidence development. While requirements considered most critical 
were largely uniform across global markets, regional nuances impacted the ability 
to obtain favorable reimbursement of implantable devices. ConClusions: Similar 
to drugs, MDs face rising hurdles in terms of demonstrating value, both clinical and 
economic. Optimal global market access for implantable MDs hinges on monitoring 
evolving evidentiary requirements and on carefully planning to collect evidence 
early in the developmental cycle.
md3
deCison making under unCertainty: Coverage with evidenCe 
development in the Context of mediCal deviCes
Sorenson C.1, Drummond M.2
1London School of Economics and European Health Technology Institute for Socio-Economic 
Research, London, UK, 2University of York, Heslington, UK
objeCtives: Coverage with evidence development (CED) is increasingly being 
used to provide provisional coverage for promising, but unproven, interventions, 
while additional data are generated. This study aimed to explore the application of 
CED in the context of devices. Methods: First, a literature review was conducted 
on international CED schemes and the CED approach more generally. In total, 50 
articles were gathered and reviewed. Second, semi-structured telephone inter-
views were conducted with different expert groups (payers/HTA bodies, industry, 
and academics/policy analysts) to better understand the use of CED in different 
jurisdictions; identify and explore device CED case studies; and, gather expert 
opinion on the challenges associated with the CED approach and potential strate-
gies to improve current policy and practice. A total of 25 experts were invited to 
participate, of which 20 (80%) agreed and were interviewed. Results: Canada, 
the UK, and US have the most experience with CED applied to devices; Germany 
and The Netherlands have both recently introduced new CED policies for devices 
and procedures. Devices that have undergone CED in these jurisdictions include 
ICDs, stents, TAVI, laparoscopic surgery, and spinal cord stimulators. While there 
are distinct differences in the national approaches to CED, common challenges 
were identified: 1) establishing a clear framework for initiating, overseeing, and 
stopping CED studies, 2) identifying and applying appropriate study methods, 3) 
funding CED studies, 4) incentivizing studies, and 5) applying new evidence to 
inform coverage decisions. ConClusions: Devices are viable candidates for CED, 
given some of their unique characteristics and often uncertain evidence base at 
the time of coverage determination. However, improvements are needed, including 
enhanced clarity and predictability of CED selection criteria and processes, greater 
stakeholder collaboration, new models to fund studies and collect data, better 
incentives for physicians to engage in studies, and strengthened requirements 
for use of new evidence in coverage policies.
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quality Criteria for the development of implant registries
Niederländer C.S., Wahlster P., Kriza C., Schaller S.U., Kolominsky-Rabas P.L.
Centre for Health Technology Assessment (HTA) and Public Health (IZPH), University of Erlangen-
Nuremberg, Erlangen, Germany
objeCtives: During the last few years, there has been a steady increase in the 
number of implant registries, mainly in the field of arthroplasty. The benefit of a 
registry depends on its content and quality. However, there are no further data 
requirements, legal and financial issues or requirements for the organizational 
(p= 0.596). ConClusions: Time preference rates were aligned with those in the pub-
lished literature but the association between time preference and adherence was non-
significant in both primary and secondary analyses at an individual country level.
Cv3
patterns of generiC and proprietary presCriBing of statins over 
time in england
Leonard S.A., Wilson T.J., Hamerslag L.
Costello Medical Consulting Ltd., Cambridge, UK
objeCtives: Given economic pressure on UK National Health Service resources, it has 
been recommended that general practitioners prescribe more low-cost, generic drugs 
as opposed to high-cost, proprietary drugs when a substitution can be made without 
compromising patient care. One of the Better Care Better Value (BCBV) indicators of good 
prescribing practice proposed by the NHS Institute for Innovation and Improvement is 
an increase in the prescription of low-cost drugs for lipid modification. The objective of 
this analysis was to evaluate patterns of generic and proprietary prescribing of statins 
from 2007–2012 inclusive. Methods: Prescription Cost Analysis databases from data.
gov.uk were reviewed between 2007–2012. Data on the number of prescription items 
dispensed each year in the community in England for simvastatin and atorvastatin (as 
commonly-prescribed examples) were extracted, along with each drug’s preparation 
class: drugs prescribed and available generically, or drugs prescribed and dispensed by 
proprietary brand name. For both simvastatin and atorvastatin, the proportions of pre-
scription items in the different preparation classes were compared each year. Results: 
Proprietary simvastatin prescription items as a proportion of all simvastatin prescription 
items decreased each year, from 2.87% in 2007 (843,000 proprietary items) to 1.76% in 
2012 (752,000 items), representing a proportional decrease of 39% in the 6-year period 
assessed. Proprietary atorvastatin prescription items as a proportion of all atorvastatin 
prescription items were close to 100% between 2007–2011 (approximately 11 million 
proprietary items each year), but fell to 30.55% in 2012 (3.9 million items), coinciding 
with the expiry of atorvastatin’s patent in May 2012. ConClusions: In England, pre-
scribing of high-cost proprietary items for these two examples of lipid-modifying drugs 
has decreased since 2007, suggesting that the BCBV prescribing indicator for statins is 
being met. Such reductions, particularly as seen with atorvastatin in 2012, are likely to 
have a significant budget impact.
Cv4
impaCt of short periods with improved or worsened inr Control on 
life expeCtanCy and qalys in patients with atrial fiBrillation
Lesén E.1, Björholt I.1, Björstad Å1, Fahlén M.2, Odén A.3
1Nordic Health Economics, Gothenburg, Sweden, 2Department of Medicine, Kungälv Hospital, 
Kungälv, Sweden, 3Department of Mathematical Sciences, Chalmers University of Technology, 
Gothenburg, Sweden
objeCtives: Warfarin-treated patients with poor international normalized ratio 
(INR) control, measured with time in therapeutic range (TTR) or the standard 
deviation of transformed INR (SDTINR), have an increased risk for clinical events. 
To what extent only a short period with an altered INR control may influence out-
comes remains unknown. This study assessed the impact of transient periods of 
improved or worsened INR control on life expectancy and quality-adjusted life years 
(QALYs) among warfarin-treated patients with atrial fibrillation (AF) using both 
metrics. Methods: Warfarin-treated patients with AF, registered in the patient 
record system Journalia during years 1985-2000, were included. Information on all-
cause mortality was collected from the Cause of Death Register. Scenarios where 
patients were assumed to have a transiently altered INR control during 30 days 
were modeled statistically using hazard functions, and the impact on remaining life 
expectancy and QALYs was assessed. Results: When using SDTINR, a 70-year old 
man within the 2.5th worst INR control percentile was estimated to gain 10.8 days of 
life or 0.0168 QALYs from a 30-day improvement in INR control to that of an average 
70-year old man. Correspondingly, 15.5 days of life or 0.0196 QALYs would be lost if a 
70-year old man within the 2.5th best INR control percentile would have an average 
INR control during 30 days. The magnitudes were smaller when TTR was used to 
determine INR control. ConClusions: Even short periods of altered INR control 
is expected to have impact on life expectancy and QALYs among patients with AF.
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Comparing virtual Colonography with Conventional ColonosCopy 
for ColoreCtal CanCer sCreening: what are the drivers of Cost-
effeCtiveness?
Kriza C.1, Emmert M.2, Wahlster P.1, Niederländer C.1, Schaller S.U.1, Kolominsky-Rabas P.L.1
1Centre for Health Technology Assessment (HTA) and Public Health (IZPH), University of 
Erlangen-Nuremberg, Erlangen, Germany, 2School of Business and Economics, Institute of 
Management, University of Erlangen-Nuremberg, Nuremberg, Germany
objeCtives: The majority of recent cost-effectiveness reviews concluded that 
computerized tomographic colonography (CTC) is not a cost-effective Colorectal 
Cancer (CRC) screening strategy yet. The objective of this review is to examine 
cost-effectiveness of CTC versus optical colonoscopy (COL) for CRC screening and 
identify the main drivers influencing cost-effectiveness due to the emergence of 
new research. Methods: A systematic review was conducted for cost-effectiveness 
studies comparing CTC and COL as a screening tool and providing outcomes in 
life-years saved, published between January 2006 and November 2012. The fol-
lowing databases were searched: PubMed, Science Direct, Cochrane Library and 
the York Centre for Reviews and Dissemination databases. The search methodol-
ogy was in line with PRISMA guidelines, including the use of the PICOS review 
system. Results: Nine studies were included in the review. There was consid-
erable heterogeneity in modelling complexity and methodology. Different model 
assumptions and inputs had large effects on resulting cost-effectiveness. The most 
important assumptions that influenced the cost-effectiveness of CTC and COL were 
related to CTC threshold-based reporting of polyps, CTC cost, CTC sensitivity for 
